Anti-SNX13 monoclonal antibody

Pre-made anti-SNX13 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SNX13/SNX13 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1783-Ab-1/ GM-Tg-hg-IP1783-Ab-2Anti-Human SNX13 monoclonal antibodyHuman
GM-Tg-rg-IP1783-Ab-1/ GM-Tg-rg-IP1783-Ab-2Anti-Rat SNX13 monoclonal antibodyRat
GM-Tg-mg-IP1783-Ab-1/ GM-Tg-mg-IP1783-Ab-2Anti-Mouse SNX13 monoclonal antibodyMouse
GM-Tg-cynog-IP1783-Ab-1/ GM-Tg-cynog-IP1783-Ab-2Anti-Cynomolgus/ Rhesus macaque SNX13 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1783-Ab-1/ GM-Tg-felg-IP1783-Ab-2Anti-Feline SNX13 monoclonal antibodyFeline
GM-Tg-cang-IP1783-Ab-1/ GM-Tg-cang-IP1783-Ab-2Anti-Canine SNX13 monoclonal antibodyCanine
GM-Tg-bovg-IP1783-Ab-1/ GM-Tg-bovg-IP1783-Ab-2Anti-Bovine SNX13 monoclonal antibodyBovine
GM-Tg-equg-IP1783-Ab-1/ GM-Tg-equg-IP1783-Ab-2Anti-Equine SNX13 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1783-Ab-1/ GM-Tg-hg-IP1783-Ab-2; GM-Tg-rg-IP1783-Ab-1/ GM-Tg-rg-IP1783-Ab-2;
GM-Tg-mg-IP1783-Ab-1/ GM-Tg-mg-IP1783-Ab-2; GM-Tg-cynog-IP1783-Ab-1/ GM-Tg-cynog-IP1783-Ab-2;
GM-Tg-felg-IP1783-Ab-1/ GM-Tg-felg-IP1783-Ab-2; GM-Tg-cang-IP1783-Ab-1/ GM-Tg-cang-IP1783-Ab-2;
GM-Tg-bovg-IP1783-Ab-1/ GM-Tg-bovg-IP1783-Ab-2; GM-Tg-equg-IP1783-Ab-1/ GM-Tg-equg-IP1783-Ab-2
Products NameAnti-SNX13 monoclonal antibody
Formatmab
Target NameSNX13
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SNX13 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1783-Ag-1Recombinant multi-species SNX13/ RGS-PX1 protein


    Target information

    Target IDGM-IP1783
    Target NameSNX13
    Gene ID23161,217463,362731,714019,475252,101085193,532001,100066218
    Gene Symbol and SynonymsmKIAA0713,RGS-PX1,SNX13
    Uniprot AccessionQ9Y5W8
    Uniprot Entry NameSNX13_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000071189
    Target ClassificationN/A

    The target: SNX13, gene name: SNX13, also named as RGS-PX1. This gene encodes a PHOX domain- and RGS domain-containing protein that belongs to the sorting nexin (SNX) family and the regulator of G protein signaling (RGS) family. The PHOX domain is a phosphoinositide binding domain, and the SNX family members are involved in intracellular trafficking. The RGS family members are regulatory molecules that act as GTPase activating proteins for G alpha subunits of heterotrimeric G proteins. The RGS domain of this protein interacts with G alpha(s), accelerates its GTP hydrolysis, and attenuates G alpha(s)-mediated signaling. Overexpression of this protein delayes lysosomal degradation of the epidermal growth factor receptor. Because of its bifunctional role, this protein may link heterotrimeric G protein signaling and vesicular trafficking. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.